Tuesday 17 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.11
0.33
−9.59%
Follow KYNB
Alert me
Where the cash went Q2 FY2026, quarter to 30 June 2026
Free cash flow was −$4.0M: capital expenditures were more than operating cash flow. Cash rose by $13.6M. What is a cash flow statement?
- Free cash flow
- −$4.0M
- Returned to shareholders
- $0.00
- Debt, net
- $0.00 borrowed
- Change in cash
- +$13.6M over the period
| Operating cash flow | 0.0 |
|---|---|
| Free cash flow | 0.0 |
| Acquisitions, net | 0.0 |
| From investments, net | 0.0 |
| Other | 0.0 |
| Change in cash | 0.0 |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more quarters Free account |
200.64 | (14.22) | (15.20) | 11.97 |
Depreciation & Amortization |
0.19 | (0.06) | (0.18) | (0.09) | |
Non Cash Items (Other) |
(42.35) | 0.80 | 1.22 | (29.96) | |
Accounts Receivable Change |
0.55 | (0.09) | (4.82) | 4.69 | |
Change in inventories |
1.03 | 0.12 | 0.36 | 0.00 | |
Accounts Payable Change |
(4.61) | (1.35) | 1.35 | 2.42 | |
Change in payables and accrued liability |
(15.47) | (3.02) | (1.42) | 8.86 | |
Change in other assets and liabilities |
(141.82) | (0.50) | 4.81 | (1.89) | |
Operating Cash Flow |
(1.85) | (18.33) | (13.89) | (3.99) | |
Capital expenditures |
(0.01) | 0.00 | — | — | |
Net Aquisitions |
90.20 | 6.41 | (0.06) | 4.00 | |
Short Term Investments Change (Net) |
(3.03) | (58.12) | (11.05) | (3.95) | |
Long-Term Investments Change (Net) |
— | — | 14.13 | 17.63 | |
Other investing activities |
— | — | — | 0.00 | |
Investing cash flow |
87.16 | (51.71) | 3.02 | 17.67 | |
Repayment/Issuance of Debt (Net) |
(80.55) | (0.01) | — | — | |
Other financial activities |
(5.36) | (0.01) | (0.01) | 0.00 | |
Financing cash flow |
(85.92) | (0.01) | (0.01) | 0.00 | |
Exchange Rate Adjustment |
(1.26) | (0.05) | 0.00 | (0.03) | |
Change in Cash |
(1.87) | (70.10) | (10.87) | 13.65 | |
Beginning Cash |
0.00 | 0.00 | 47.87 | 0.00 | |
Ending Cash |
(1.87) | (70.10) | 37.00 | 13.65 | |
Stock Based Compensation |
0.66 | 1.19 | 1.15 | 0.98 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(160.33) | (4.84) | 0.27 | 14.08 | |
Investments Change (Net) |
(3.03) | (58.12) | 3.08 | 13.68 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026